Eloralintide
Aliases: LY3841136
Last verified: 2026-09-24
The short version
Eloralintide is the most interesting new molecule in the 'post-GLP-1' space that actually differs in mechanism: an amylin, not incretin, receptor — the first serious candidate outside the GLP-1 family. Phase 2 is impressive (up to ~20% weight loss, apparently on par with tirzepatide), with two caveats: 263 participants across 46 centers is thin ground for such numbers, and 64% nausea in the highest arm shows that amylin selectivity does not mean a free tolerability lunch. But this is a real clinical substance with a real development path — unlike 99% of gray-market listings. If phase 3 confirms phase 2, it is a new drug class; if not, a classic lesson from the obesity field.
Identity & type
- Molecular type
- analog
- Origin
- A synthetic amylin analog with lipid conjugation; designed for AMY1R selectivity, low immunogenicity and aggregation resistance.
Mechanism of action
A selective, long-acting agonist of the amylin 1 receptor AMY1R (12× more potent at AMY1R than at the calcitonin receptor), conjugated to a C20 fatty diacid for reversible albumin binding; a ~14-day half-life enables once-weekly dosing; it does not act on the GLP-1 receptor — a different mechanism from all mainstream obesity drugs.
Dosing & routes
Official / clinical context
Trial framework only: ClinicalTrials.gov records (NCT06230523 et al.); no regulatory approval in any country.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Gray presence is paradoxical: the 'research' eloralintide circulating in the community is a chemical of non-GMP origin, while the real molecule exists only in Lilly-supervised trials. Any 'protocol' with a gray product has nothing to do with what The Lancet shows.
Unverified self-reports. Not medical advice. Not endorsement.
Protocol — official vs community
Official / label
Investigational long-acting amylin analogue (Eli Lilly), phase 2. SC weekly.
- 01Phase 2 explored weekly escalation to ~9 mg over 24 weeks
Duration: Trial-defined.
Amylin-class monotherapy; positioned as a gentler alternative to GLP-1 combinations.
Community (anecdotal)
None — no legitimate supply.
- Cycle:
- —
- Break:
- —
Pre-approval molecule; any vial is unverifiable.
Human evidence
Moderate and growing: one published randomized phase 2 (48 weeks, 263 participants) with a strong dose-response; phase 3 ongoing. A second phase 2 is a future event — 'moderate' is the currently accurate rating.
Preclinical evidence
The standard preclinical package for this class; not the questionable part of the story.
Known risks
- Dose-dependent nausea and fatigue (phase 2 profile)characterized
- Tested only up to 48 weeks — long-term safety unknowntheoretical
- Gray product ≠ trial product (aggregation/identity)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Phase 3 results (expected ~2028)
- Effect and tolerability in combination with tirzepatide
- Long-term cardiovascular-renal profile
Frequently asked questions
References
- Billings LK et al. Eloralintide phase 2, 48-week RCT. Lancet, 2025 (PMID 41207310)
- Eloralintide phase 1b MAD trial. Diabetes Obes Metab, 2024
- Eli Lilly pipeline — eloralintide phase 3 program